Acute Promyelocytic Leukemia

• CLINICAL_TRIALS approval · 2018-03-02
  Clinical Trial Update: Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

  Gemtuzumab ozogamicin has been approved for marketing for relapsed or refractory acute myeloid leukemia and acute promyelocytic leukemia bas…

• FDA approval · 2018-01-12
  FDA Approved: TRISENOX — Supplemental Application (Cephalon, LLC)

  The FDA approved a supplemental application for TRISENOX (arsenic trioxide) by Cephalon, LLC.

• FDA approval · 2015-02-20
  FDA Approved: TRISENOX — Supplemental Application (Cephalon, LLC)

  FDA approved a supplemental application for Trisenox (arsenic trioxide) submitted by Cephalon, LLC.

• FDA approval · 2010-07-23
  FDA Approved: TRISENOX — Supplemental Application (Cephalon, LLC)

  FDA approves a supplemental application for TRISENOX (arsenic trioxide) submitted by Cephalon, LLC.

• FDA approval · 2007-02-21
  FDA Approved: TRETINOIN — Supplemental Application (Padagis US LLC)

  The FDA approved a supplemental application for tretinoin from Padagis US LLC, indicating an update to an existing product's labeling or man…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2007-02-21
  FDA Approved: TRETINOIN — Supplemental Application (Padagis US LLC)

  FDA approved a supplemental application for tretinoin by Padagis US LLC, authorizing changes to the approved generic product.

• FDA approval · 2007-02-21
  FDA Approved: TRETINOIN — Supplemental Application (Padagis US LLC)

  The FDA approved a supplemental application for tretinoin submitted by Padagis US LLC, authorizing changes to the product's labeling under A…